| Assessment Status |
NCPE assessment ongoing |
| HTA ID |
22018 |
| Drug |
Cabozantinib/Nivolumab |
| Brand |
Cabometyx®/Opdivo® |
| Indication |
First-line treatment of advanced renal cell carcinoma in adults. |
| Rapid review commissioned |
28/03/2022 |
| Rapid review completed |
11/05/2022 |
| Rapid review outcome |
A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of cabozantinib (Cabometyx®) in combination with nivolumab compared with the current standard of care, on the basis of the proposed price relative to currently available therapies. |
| Full pharmacoeconomic assessment commissioned by HSE |
27/05/2022 |
| Pre-submission consultation with Applicant |
13/08/2024 |
| Full submission received from Applicant |
12/12/2024 |
| Preliminary review sent to Applicant |
05/06/2025 |
| NCPE assessment re-commenced |
07/07/2025 |
